ACIU - יחס חוב להיוון בספרים AC Immune S.A.

AC Immune (ACIU) relies on professional Swiss management that ensures transparency in the development of Parkinson's and Alzheimer's drugs. Alliances with global industry behemoths guarantee an influx of investment, with the current figure standing at 0.13. This chart on the GURU.Markets platform visualizes the price action of this Swiss developer, which focuses on finding innovative therapies for neurodegenerative pathologies.

Given the binary risks associated with AC Immune (ACIU) developments in Alzheimer's therapy, the debt-to-equity dynamics on GURU.Markets allow for an assessment of the company's financial stability. This ratio compares total debt to shareholders' equity, demonstrating the business's degree of leverage and its ability to withstand market shocks without compromising solvency.